Anemocyte achieves the Gender Equality Certification (UNI/PdR 125:2022)
Anemocyte is pleased to announce it has achieved the Gender Equality Certification, in accordance with the national reference practice UNI/PdR 125:2022.
read moreAMCAPTM | AMClarity | People & Career | News |
Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
Anemocyte is pleased to announce it has achieved the Gender Equality Certification, in accordance with the national reference practice UNI/PdR 125:2022.
read moreAnemocyte will attend Advanced Therapies Week 2026, one of the leading US partnering and content events for the cell & gene therapy (CGT) ecosystem, hosted by Phacilitate. The conference will take place at the San Diego Convention Center in San Diego on February 9–12, 2026.
read moreAnemocyte is pleased to announce the publication of its 2024 Sustainability Report, a key milestone that reflects the company’s ongoing commitment to responsible growth, transparency, and long-term value creation.
read moreWe are excited to announce that Advanced Therapies USA 2025 (November 18-19, Philadelphia) will bring together the entire ecosystem of advanced therapies – and we at Anemocyte are proud to be part of it.
read moreAnemocyte Srl is set to make a significant contribution to the 13th International mRNA Health Conference in Berlin and online, from November 11 to 13, 2025.
read moreAnemocyte will participate in TIDES Europe 2025, taking place in Basel, Switzerland, from 11 to 13 November 2025.
read moreGenenta Science and ANEMOCYTE, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform.
read moreAnemocyte is pleased to announce its participation in CPHI Europe 2025, taking place in Frankfurt, Germany, from October 28 to 30, 2025, at Messe Frankfurt.
read moreWe are delighted to announce Anemocyte’s participation in BioJapan / Regenerative Medicine Japan / healthTECH Japan 2025, taking place from October 8–10, 2025 at PACIFICO Yokohama.
read moreWe are proud to announce Anemocyte’s participation in the Cell & Gene Meeting on the Mesa, taking place in Phoenix, Arizona, from October 6 to 8, 2025.
read moreWe’re proud to announce that we’ll be attending the 2nd Annual Meeting of the Society for mRNA Medicines, in Coronado (CA) from September 16–18, 2025.
read moreWe’re thrilled to announce that our team will participate in RNA Leaders USA 2025, taking place in Boston on September 10-11
read moreOff the Shelf mRNA, pDNA and IVT Kit solutions
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961